Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMI and Fludarabine for Relapsed/Refractory Hematologic Malignancies
NCT03696537Phase 1Terminated
- Start
- Aug 2018
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of fludarabine in acute myeloid leukemia (AML), Chronic Myeloid Leukemia (CML), acute lymphoblastic leukemia (ALL) and 1 more. Primary endpoints: Dose limiting toxicity at 37 days and Maximum-tolerated dose at 37 days. Started Aug 2018; status: terminated.
02
Drugs
fludarabine
03
Conditions
acute myeloid leukemia (AML)Chronic Myeloid Leukemia (CML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03696537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696537.